Yen, Chia-Jui
Kaohsiung Veterans General Hospital · National Cheng Kung University Hospital · Meiho University · National Cheng Kung University
6 papers on CoChatORCID 0000-0001-8744-6248
Most cited papers
- Verified
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet
Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers
Cited by 3,336
- Verified
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet
Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments
Cited by 1,169
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology
Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers
Cited by 690
- Verified
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 365
- Verified
Second harmonic generation microscopy reveals the spatial orientation of glutamine-potentiated liver regeneration after hepatectomy
Yen, C.-C., Yen, C.-S., Tsai, H.-W., Yeh, M. M., Hong, T.-M., Wang, W.-L., Liu, I.-T., Shan, Y.-S., & Yen, C.-J. (2025) · Hepatology Communications
Liver physiology and pathologyTissue Engineering and Regenerative Medicine
Cited by 4
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free